US Archives - Page 152 of 173 - European Medical Journal

24-Hour Therapy for Parkinson’s: The First Of Its Kind

The U.S. FDA has approved a 24-hour continuous subcutaneous infusion for adults with advanced Parkinson’s disease. This therapy is the first of its kind.

Pre-Exposure Prophylaxis Uptake Across US: IDWeek 2024

Use of pre-exposure prophylaxis (PrEP), an HIV-1 prevention strategy, across diverse demographic groups is not consistent, despite importance of the tool.

National Trends in Sepsis Rates in Children: IDWeek 2024

New data presented at IDWeek 2024, October 16-19, alerted doctors about the national trends and racial disparities in sepsis-related mortality rates (SRMR) in children between 1999 to 20219.

How Do Extreme Temperatures Affect Raynaud’s Phenomenon?

Hot and cold outdoor temperatures significantly worsen Raynaud’s phenomenon in patients with systemic sclerosis, according to new research.

How Long Do Antibiotics Take To Work? 7-Day Change: IDWeek 2024

New research presented at IDWeek 2024 may impact advice patients are given on how long antibiotics take to work following treatment of bloodstream infections.

Home Phototherapy for Psoriasis: Convenient and Effective

A major randomized clinical trial has demonstrated that home-based narrowband UV-B phototherapy is as effective as office-based treatment for patients with plaque or guttate psoriasis.

Avian Flu Detected Early in Wastewater: IDWeek 2024

Avian influenza H5 was detected in municipal wastewater solids during a U.S. cattle outbreak, providing a potential early warning system for future outbreaks.

What’s the Link Between Traumatic Brain Injury and Alzheimer's?

Traumatic brain injury accounts for 30% of all injury-related deaths in the United States, and is a major cause of death and disability in the country.

Personalized Immunotherapy for Resistant Lung Cancer Mutations

A new study from The University of Texas MD Anderson Cancer Center has revealed that a combination of dual immunotherapy and chemotherapy improves outcomes for patients with metastatic NSCLC who harbor specific mutations.

New Research in HSV-2 Recurrence Therapy

HSV-1 and HSV-2 establish latent/reactivation patterns, giving rise to recurrent epithelial lesions, cold sores and genital herpes, in patients. These persistent infections have affected over half of the US adult population yet the pathogenic mechanism is not well understood.